Anti-C-EBP alpha Antibody, clone 2E17, ZooMAb® Rabbit Monoclonal
SIGMA/ZRB1367 - recombinant, expressed in HEK 293 cells
Synonym: C/EBP alpha; CCAAT/
Product Type: Chemical
antibody form | purified antibody |
antibody product type | primary antibodies |
biological source | rabbit (recombinant) |
clone | 2E17, monoclonal |
recombinant monoclonal | |
conjugate | unconjugated |
enhanced validation | recombinant expression Learn more about Antibody Enhanced Validation |
form | lyophilized |
greener alternative category | Aligned |
greener alternative product characteristics | Waste Prevention Designing Safer Chemicals Design for Energy Efficiency Learn more about the Principles of Green Chemistry . |
isotype | IgG |
mol wt | calculated mol wt 37.56 kDa |
observed mol wt ~50 kDa | |
packaging | pkg of 25 μL |
product line | ZooMAb® learn more |
recombinant | expressed in HEK 293 cells |
shipped in | ambient |
species reactivity | human, mouse |
storage temp. | 2-8°C |
technique(s) | flow cytometry: suitable |
immunocytochemistry: suitable | |
western blot: suitable | |
UniProt accession no. | P49715 |
Application: | Anti-C-EBP alpha, clone 2E17 ZooMAb, Cat. No. ZRB1367, a recombinant Rabbit monoclonal antibody that specifically targets C-EBP alpha and has been tested for use in Flow Cytometry, Immunocytochemistry, and Western Blotting. |
Application: | Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected C-EBP alpha in THP-1 cell lysate. Flow Cytometry Analysis: 0.01 μg from a representative lot detected C-EBP alpha in one million U937 cells. Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected C-EBP alpha in THP-1 cells. Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user. |
Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
General description: | We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information. |
General description: | ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them. Learn more about ZooMAb here. |
Immunogen: | GST/His-tagged recombinant fragment corresponding to 147 amino acids from N-terminal region of human C-EBP alpha, isoform 1. |
Legal Information: | ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany |
Physical form: | Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL. |
Reconstitution: | 30 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type. |
Specificity: | Clone 2E17 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects C-EBP alpha. It targets an epitope within 147 amino acids from the N-terminal region. |
Storage and Stability: | Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws. |
Target description: | CCAAT/enhancer-binding protein alpha (UniProt: P49715; also known as C/EBP alpha, C-EBP alpha) is encoded by the CEBPA (also known as CEBP) gene in human. C-EBP alpha belong to the bZIP family of proteins that serves as a transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. It binds directly to the consensus DNA sequence 5′-T[TG]NNGNAA[TG]-3′ acting as an activator on distinct target genes. It can bind DNA as a homodimer or as a stable heterodimer with CEBPB, CEBPD, CEBPE, and CEBPG. It is reported to be essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP) and has also been shown to be critical for the proper development of the liver and the lung and for terminal adipocyte differentiation. C-EBP alpha down-regulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. It can be phosphorylated on multiple sites. Phosphorylation at serine 190 is shown to be essential for its interaction with CDK2, CDK4 and SWI/SNF complex leading to cell cycle inhibition. Phosphorylation at threonine 226 and threonine 230 by GSK3 is constitutive in adipose and lung tissue and these sites are also shown to be phosphorylated in liver during feeding, but not during fasting cycle. Four isoforms of C-EBP alpha have been described that are produced by alternative splicing. Mutations in CEBPA gene are known to cause acute myelogenous leukemia (AML). This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Wedel, A., et al. (1995). Immunobiology. 193(2-4); 171-185; Johnson, PF et al. (2005). J. Cell Sci. 118(12); 2545-2555). |
WGK Germany | WGK 1 |
Storage Temp. | 2-8°C |
UNSPSC | 12352203 |